March 2016

Scientists use stem cells to regrow spinal cords

The California Institute for Regenerative Medicine (CIRM)'s Independent Citizens Oversight Committee has approved a $6.3 million grant to fund a research team's work ... damaged as a outcome of amyotrophic lateral sclerosis (ALS). Humans need corticospinal ...

Personalized Natural Killer (NK) Cell Therapy in Cord Blood Transplantation (CBT)

Conditions:   Leukemia;   Lymphoma;   Myeloma;   Myeloproliferative Diseases
Interventions:   Drug: Busulfan;   Drug: Fludarabine;   Drug: Clofarabine;   Drug: Rabbit ATG;   Radiation: Total Body Irradiation (TBI);   Procedure: Cord Blood Infusions;   Drug: Rituximab;   Drug: Cyclophosphamide;   Procedure: Natural Killer Cell Infusion;   Drug: Melphalan;   Drug: Mesna
Sponsor:   M.D. Anderson Cancer Center
Recruiting - verified December 2016

UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep

Conditions:   Acute Leukemia;   Acute Myeloid Leukemia;   Acute Lymphoblastic Leukemia/Lymphoma;   Burkitt's Lymphoma;   Natural Killer Cell Malignancies;   Chronic Myelogenous Leukemia;   Myelodysplastic Syndrome;   Large-cell Lymphoma;   Hodgkin Lymphoma;   Multiple Myeloma;   Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma;   Marginal Zone B-cell Lymphoma;   Follicular Lymphoma;   Lymphoplasmacytic Lymphoma;   Mantle-cell Lymphoma;   Prolymphocytic Leukemia;   Bone Marrow Failure Syndromes;   Myeloproliferative Syndromes

Use of Dalfampridin in Primary Lateral Sclerosis

Condition:   Motor Neuron Disease, Upper
Intervention:   Drug: dalfampridine
Sponsors:   Weill Medical College of Cornell University;   Hospital for Special Surgery, New York
Recruiting - verified November 2016

ALS Reversals - Lunasin Regimen

This is a 12-month, widely inclusive, largely virtual, single-center, open-label pilot trial utilizing a historical control group. Participants will receive a Lunasin regimen and will be asked to register for an account of PatientsLikeMe website, where after the initial in-clinic visit, they will be asked to enter specific data.

Condition:             ALS (Amyotrophic Lateral Sclerosis)
Interventions:       Drug: Lunasin Regimen;   Other: Historical control
Sponsor:               Richard Bedlack, M.D., Ph.D.

Active, not recruiting - verified May 2016